Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Milestone Scientific ( (MLSS) ) has shared an announcement.
On May 14, 2025, Milestone Scientific Inc. appointed Shanth Thiyagalingam as an independent director. Thiyagalingam, currently CEO of PainTEQ, has extensive experience in the medical device industry, having held leadership roles at Abbott Laboratories and Nevro Corporation. The appointment, announced on May 19, 2025, is expected to strengthen the company’s board with Thiyagalingam’s expertise in medical equipment and healthcare.
The most recent analyst rating on (MLSS) stock is a Buy with a $1.25 price target. To see the full list of analyst forecasts on Milestone Scientific stock, see the MLSS Stock Forecast page.
Spark’s Take on MLSS Stock
According to Spark, TipRanks’ AI Analyst, MLSS is a Neutral.
Milestone Scientific’s overall score reflects a blend of significant strengths and ongoing challenges. The company shows promise with its strong gross margins, low leverage, and strategic initiatives highlighted in the earnings call, particularly in the medical division. However, persistent financial losses, negative cash flows, and valuation concerns weigh negatively. Technical indicators suggest lackluster momentum, contributing to a cautious outlook for the stock.
To see Spark’s full report on MLSS stock, click here.
More about Milestone Scientific
Average Trading Volume: 76,461
Technical Sentiment Signal: Sell
Current Market Cap: $70.24M
Find detailed analytics on MLSS stock on TipRanks’ Stock Analysis page.